Phase II study of vindesine in patients with advanced breast cancer.

Abstract

Vindesine, a new vinca alkaloid, was administered to 20 patients with advanced refractory breast cancer in a phase II trial. The drug was given at a dose of 3 mg/m2 by iv bolus each week for 6 consecutive weeks, and responding patients were maintained on a dose of 4 mg/m2 every 2 weeks. Nineteen patients were evaluable for disease response; partial remissions were obtained in five patients, for a response rate of 26%. Leukopenia was the major dose-limiting toxic reaction, but most patients were able to tolerate this schedule without difficulty. Neurotoxicity was mild and did not require dose reduction.

• Authors: B K Walker, P C Raich, J Fontana, V P Subramanian, J S Rogers 2nd, J A Knost, B Denning
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 66 Issue 9 Pg. 1729-32 (Sep 1982) ISSN: 0361-5960 [Print] United States
• PMID: 6288237 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Vinblastine
• Vindesine

Topics

• Aged
• Anemia (chemically induced)
• Breast Neoplasms (drug therapy, pathology)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Middle Aged
• Peripheral Nervous System Diseases (chemically induced)
• Platelet Count (drug effects)
• Time Factors
• Vinblastine (adverse effects, analogs & derivatives, therapeutic use)
• Vindesine